The study systematically investigated adverse drug reactions associated with ophthalmic atropine using the FAERS database, where they analyzed 425 reports and identified 83 positive signals. Signals mainly included eye disorders, nervous system disorders, injuries, poisonings, procedural complications, and infections. The most frequent and strongest signal was endophthalmitis (n = 74, IC025 = 6.62, ROR025 = 101.90). Other significant signals were choroiditis (IC025 = 6.05, ROR025 = 69.26), increased intraocular pressure (IC025 = 5.77, ROR025 = 56.93), reduced visual acuity (IC025 = 5.46, ROR025 = 43.34) and uveitis (IC025 = 5.36, ROR025 = 56.93). ROR025 = 42.93). Eye pain (n = 64, IC025 = 4.99, ROR025 = 32.90) was another commonly reported reaction. Of the preferred terms, 81.93% had low clinical priority and 18.07% medium. The conclusion emphasizes the need for increased clinical vigilance with ophthalmic atropine, with signals not being proof of causality or an estimate of incidence.